Skip to main navigation
Logo

SEC Filings

SEC Filings

Form Description Filing date View
3

Initial filing by director officer or owner of more than ten percent.

May 5, 2016
0001209191-16-117931.pdf
0001209191-16-117931.rtf
0001209191-16-117931.xls
View HTML
D/A

Notice of Exempt Offering of Securities

March 24, 2015
0001619856-15-000001.pdf
0001619856-15-000001.rtf
0001619856-15-000001.xls
View HTML
D

Notice of Exempt Offering of Securities

September 23, 2014
0001619856-14-000001.pdf
0001619856-14-000001.rtf
0001619856-14-000001.xls
View HTML

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Current page 11

Data provided by Kaleidoscope.

 

 


Toolkit

Print Page

Email Alerts

RSS Feeds

Investor Contact

Main Menu

  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
  • More
    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Collaborations
      • Licenses
    • Technology
      • Allogeneic T cells
      • Allogeneic NK cells
      • chRDNAs
      • Publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • Clinical Trials
    • Careers
      • Job Opportunities
      • Values
      • Spotlights
      • Benefits
        • Summary of Benefits
    • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Leadership
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
        • Annual Reports
        • Quarterly Results
      • IR Resources
        • FAQs
        • Email Alerts
        • Contact IR
    • Contact

    Main Menu

    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Collaborations
      • Licenses
    • Technology
      • Allogeneic T cells
      • Allogeneic NK cells
      • chRDNAs
      • Publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • Clinical Trials
    • Careers
      • Job Opportunities
      • Values
      • Spotlights
      • Benefits
        • Summary of Benefits
    • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Leadership
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
        • Annual Reports
        • Quarterly Results
      • IR Resources
        • FAQs
        • Email Alerts
        • Contact IR
    • Contact

    logo

    Caribou Biosciences, Inc.
    2929 7th Street, Suite 105
    Berkeley, CA 94710
    Tel: 510-982-6030
    info@cariboubio.com

    ©  Caribou Biosciences, Inc. All rights reserved.

    02. Footer Copyright Links

    • Privacy Policy
    • Terms of Use

    03. Footer Social Links

    • Twitter
    • linkedin